Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael MacalusoAccesswire • 11/16/22
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023Accesswire • 11/14/22
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term LoanAccesswire • 10/25/22
Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development ProgramsAccesswire • 10/13/22
Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply DisruptionsAccesswire • 10/05/22
Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call TranscriptSeeking Alpha • 09/28/22
Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022Accesswire • 09/20/22
Aytu BioPharma Announces Addition of Fourth Patent License for AR101/EnzastaurinAccesswire • 09/14/22
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth ConferenceAccesswire • 07/26/22
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of DirectorsAccesswire • 06/29/22
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor ConferenceAccesswire • 06/13/22
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic PrioritiesAccesswire • 05/16/22
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery TechnologyAccesswire • 04/25/22
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)Accesswire • 03/23/22
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease SummitAccesswire • 03/22/22